Media Room Menu
Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
May 12, 2021Libtayo is the first immunotherapy to demonstrate an improvement in overall survival in advanced cervical cancer, as well as progression-free survival and objective response rate, compared to chemotherapy
-
May 6, 2021Sanofi establishes three-year collaboration with Stanford Medicine to accelerate immunology research* Projects led by collaborating researchers from the two organizations will focus on autoimmune diseases and inflammatory conditions